Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P.

RA Capital Management L.P. lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 50.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,061,233 shares of the company's stock after selling 1,061,232 shares during the quarter. RA Capital Management L.P. owned 2.25% of Enliven Therapeutics worth $27,104,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ELVN. Patient Square Capital LP bought a new stake in shares of Enliven Therapeutics in the 3rd quarter worth about $2,313,000. Janus Henderson Group PLC raised its holdings in shares of Enliven Therapeutics by 43.0% in the third quarter. Janus Henderson Group PLC now owns 1,041,724 shares of the company's stock worth $26,611,000 after buying an additional 313,019 shares during the period. Verition Fund Management LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter worth approximately $271,000. Walleye Capital LLC purchased a new position in Enliven Therapeutics during the 3rd quarter valued at $2,539,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Enliven Therapeutics by 12.7% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 26,168 shares of the company's stock valued at $668,000 after acquiring an additional 2,944 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 847 shares of the business's stock in a transaction on Friday, October 18th. The stock was sold at an average price of $30.00, for a total transaction of $25,410.00. Following the transaction, the insider now directly owns 1,015,188 shares in the company, valued at $30,455,640. The trade was a 0.08 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $24.27, for a total value of $103,147.50. The disclosure for this sale can be found here. Insiders have sold 129,195 shares of company stock worth $3,581,772 over the last quarter. Insiders own 29.20% of the company's stock.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded down $0.47 during midday trading on Thursday, hitting $23.24. 26,799 shares of the company traded hands, compared to its average volume of 255,691. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $30.03. The company's 50-day simple moving average is $26.78 and its 200-day simple moving average is $24.14. The company has a market cap of $1.14 billion, a PE ratio of -12.48 and a beta of 1.02.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird increased their price objective on Enliven Therapeutics from $32.00 to $40.00 and gave the stock an "outperform" rating in a research note on Friday, November 15th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.